IFN treatment, especially in patients achieving a sustained viral response, reduces risk of HCC [40] but maintenance treatment with pegylated IFN was not found effective in the HALT-C trial [41, 42]. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.